In conclusion, our results indicate that the pHER2Y1248-negative status of HER2-overexpressing BC represents a strong independent predictor of tumor resistance to trastuzumab-based therapy and poor five-year DFS rate irrespective of other biomarkers and clinicopathological variables tested. This evidence concerns the gene ERBB2 and breast cancer.